Introduction
============

Ovarian cancer is the second most common gynecologic malignancy and is the leading cause of death from gynecologic cancers worldwide.[@b1-dddt-12-3013],[@b2-dddt-12-3013] Typically, ovarian cancer presents with advanced stages at the time of diagnosis.[@b3-dddt-12-3013] Although most patients with advanced ovarian cancer initially receive platinum-based chemotherapy and achieve a clinical response, the effectiveness of the treatments diminishes over time, and most of these patients will ultimately relapse.[@b4-dddt-12-3013]--[@b6-dddt-12-3013] The prognosis of these recurrent ovarian cancer patients is very poor, with a median survival ranging from 12 months to 24 months.[@b7-dddt-12-3013] Clearly, novel effective drugs or treatment strategies that can improve long-term disease control in recurrent ovarian cancer are urgently needed.[@b8-dddt-12-3013]

Recent advances in the understanding of the molecular biology and mechanism of epithelial ovarian cancer have led to the development of a number of targeted therapies, including poly-ADP-ribose polymerase inhibitors (PARPis).[@b9-dddt-12-3013],[@b10-dddt-12-3013] PARPis are a novel class of therapeutic agents that target tumors with deficiencies in the homologous recombination DNA repair pathway. Until now, three PARPis olaparib,[@b11-dddt-12-3013] niraparib,[@b12-dddt-12-3013] and rucaparib[@b13-dddt-12-3013] have been approved for use in ovarian cancer by the US Food and Drug Administration. As these drugs have now entered routine clinical practice, more and more patients would receive PARPis, and concerns increase regarding the toxicities associated with the administration of PARPis. In a previously published meta-analysis conducted by Zhou et al,[@b14-dddt-12-3013] the authors found that treatment with the PARPis olaparib, veliparib, and niraparib was associated with a significant increase in the risk of developing hematologic toxicities in cancer patients. Gastrointestinal (GI) toxicities associated with PARPis have been reported in clinical trials, but the results are controversial.[@b15-dddt-12-3013],[@b16-dddt-12-3013] As a result, we conducted the present meta-analysis of all available trials to comprehensively assess the overall incidence and risk of selected GI toxicities (nausea, vomiting, diarrhea, and constipation) associated with PARPis in the treatment of ovarian cancer.

Materials and methods
=====================

Data source
-----------

Several databases including PubMed, Web of Science and Cochrane library were searched for relevant trials. The search key words were PARPis, olaparib, veliparib, niraparib, rucaparib and ovarian cancer. Additionally relevant articles in the reference lists of recent meta-analyses that investigated PARPis in ovarian cancer patients were also searched. In order to avoid duplication, only the most complete or recent was considered for analysis. All results were input into End-note X8 reference software (Thomson Reuters, Stamford, CT, USA) for duplication exclusion and further reference management. Finally, the most updated package inserts of olaparib, niraparib, and rucaparib were reviewed to identify other relevant information. Trials were chosen and reviewed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.[@b17-dddt-12-3013]

Study selection
---------------

The primary objective of the present study was to evaluate the overall incidence of PARPis-related GI toxicities and the risk of GI toxicities in ovarian cancer patients treated with PARPis; therefore, only prospective phase II and III trials evaluating PARPis in ovarian cancer patients with adequate data on GI toxicities were incorporated in the analysis. Phase I trials were omitted due to multiple dose level and limited sample sizes. Clinical trials that met the following criteria were included as follows: 1) prospective phase II and III trials, expanded access protocols (EAPs); 2) participants assigned to treatment with PARPis (alone or in combination at any dosage or frequency); and 3) available data regarding events or incidence of GI toxicities and sample size. Phase I trials were excluded because of inter-study variability in drug dosing as well as the small number of patients in these trials.

Data extraction
---------------

Two investigators independently conducted data abstraction, and any discrepancy between the reviewers was resolved by consensus. Most of the incorporated trials have used the common terminology criteria of adverse events version 4.0 for grading of the relevant adverse events. A checklist of necessary data to be extracted from each study included: first author's name, year of publication, phases of trials, number of enrolled subjects, treatment arms, number of patients in treatment and controlled groups, median age, median progression-free survival, and the number of each of the selected GI adverse events.

Statistical analysis
--------------------

The primary summary measures were incidence, relative risk (RR), and corresponding 95% CIs of all grade (grade 1--4) and high-grade (grade 3--4) selected GI toxicities. All statistical analyses were performed by using Version 2 of the Comprehensive MetaAnalysis program (Biostat, Englewood, NJ, USA). For the calculation of incidence, the number of patients with selected GI toxicities in PARPis alone and the total number of patients receiving PARPis alone were extracted. To calculate RR, patients assigned to PARPis were compared only with those assigned to control treatment in the same trial. Between-study heterogeneity was estimated using the *χ*^2^-based Q statistic.[@b18-dddt-12-3013] Heterogeneity was considered statistically significant when *P*~heterogeneity~ \<0.1. The presence of publication bias was evaluated by using the Begg and Egger tests.[@b19-dddt-12-3013],[@b20-dddt-12-3013] A statistical test with a *P*-value \<0.05 was considered significant.

Results
=======

Search results
--------------

Our search yielded 240 potentially relevant citations on PARPis from the searched databases. The details for the study inclusion/exclusion procedure are illustrated in [Figure 1](#f1-dddt-12-3013){ref-type="fig"}. A total of 12 trials were considered eligible for the analysis, including three Phase III trials[@b21-dddt-12-3013]--[@b23-dddt-12-3013] and nine Phase II trials.[@b24-dddt-12-3013]--[@b32-dddt-12-3013] A total of 2,286 patients were included in this analysis. Most patients had a performance score between 0 and 2 and competent liver, kidney and bone marrow function. The baseline patients' characteristics in each trial are described in [Table 1](#t1-dddt-12-3013){ref-type="table"}.

Overall incidence of relevant adverse events
--------------------------------------------

For the incidence analysis, we considered ovarian cancer patients receiving PARPis monotherapy. The pooled incidence of all-grade nausea, vomiting, diarrhea, and constipation was 68.8% (95% CI, 63.5%--73.6%), 36.2% (95% CI, 30.9%--41.8%), 25.3% (95% CI, 21.2%--29.8%), and 25.3% (95% CI, 17.9%--34.5%), respectively. There was significant heterogeneity among trials, and we thus performed the meta-analysis by using a random-effects model ([Table 2](#t2-dddt-12-3013){ref-type="table"}). As for high-grade GI toxicities, the pooled incidence of GI toxicities associated with PARPis was nausea 3.4% (95% CI, 2.6%--4.5%), vomiting 2.0% (95% CI, 1.4%--3.0%), diarrhea 1.7% (95% CI, 1.0%--3.0%), and constipation 1.4% (95% CI, 0.9%--2.3%), respectively. There was no significant heterogeneity among included trials, and we thus performed the meta-analysis by using a fixed-effects model ([Table 2](#t2-dddt-12-3013){ref-type="table"}).

RR of all-grade relevant GI toxicities
--------------------------------------

A meta-analysis of the RR of all-grade adverse events was performed on the included randomized controlled trials (RCTs), which contained a direct comparison between PARPis and control treatment. The RRs of all-grade nausea, vomiting, diarrhea, and constipation were 2.00 (95% CI: 1.79--2.24; *P*\<0.001, [Figure 2A](#f2-dddt-12-3013){ref-type="fig"}), 2.12 (95% CI: 1.75--2.58; *P*\<0.001, [Figure 2B](#f2-dddt-12-3013){ref-type="fig"}), 1.20 (95% CI: 1.01--1.44; *P*=0.044, [Figure 2C](#f2-dddt-12-3013){ref-type="fig"}), 1.26 (95% CI: 0.88--1.20); *P*\<0.001, [Figure 2D](#f2-dddt-12-3013){ref-type="fig"}); respectively. Thus, patients treated with PARPis had an increased risk of developing all-grade nausea, vomiting, diarrhea, and constipation. The fixed effects model was used for all the evaluated toxicities, except for constipation.

RR of high-grade relevant GI toxicities
---------------------------------------

RCTs directly comparing PARPis with control treatment were included to calculate RRs of high-grade GI toxicities. The RR of high-grade nausea, vomiting, diarrhea, and constipation were 3.74 (95% CI: 1.50--9.36; *P*=0.005, [Figure 3A](#f3-dddt-12-3013){ref-type="fig"}), 2.81 (95% CI: 1.17--6.74; *P*=0.02, [Figure 3B](#f3-dddt-12-3013){ref-type="fig"}), 0.56 (95% CI: 0.22--1.43; *P*=0.23, [Figure 3C](#f3-dddt-12-3013){ref-type="fig"}), 0.92 (95% CI: 0.34--2.49, *P*=0.87, [Figure 3D](#f3-dddt-12-3013){ref-type="fig"}); respectively. Thus, patients treated with PARPis had an increased risk of developing high-grade nausea and vomiting, but not for high-grade diarrhea and constipation. The fixed effects model was used for all evaluated toxicities.

Discussion
==========

To the best of our knowledge, this is the most comprehensive and up-dated meta-analysis to provide an investigation of overall incidence and risk of GI toxicities in ovarian cancer patients treated with PARPis. Our analysis of data demonstrates that the risk of all-grade gastrointestinal toxicities associated with PARPis is significantly increased in the treatment of ovarian cancer. In addition, the use of PARPis in ovarian cancer significantly increases the risk of developing high-grade nausea and vomiting, but not for diarrhea and constipation. The four PARPis evaluated within our analysis are olaparib, veliparib, niraparib, and rucaparib. And three of them olaparib, niraparib, and rucaparib have been approved for use in ovarian cancer due to their survival benefits. Additionally, a number of ongoing Phase II and III studies are assessing these agents in multiple other solid tumors indications.[@b33-dddt-12-3013],[@b34-dddt-12-3013] Therefore, the use of PARPis is anticipated to increase in the near future, and clinicians should pay particular attention to regular monitoring of GI toxicities related to PARPis during the administration of these drugs.

Until now, GI toxicities are considered an important cause for treatment interruption and/or permanent discontinuation in the clinical trials. Although high-grade GI toxicities are relatively uncommon, there are currently no methods to predict patients at highest risk, and thus regular monitoring of clinical parameters during the administration of these drugs is warranted. Generally, administration of supportive therapy should be undertaken with the earliest manifestation of nausea and vomiting experienced by ovarian cancer patients treated by PARPis.

However, as far as we know, there are no specific guidelines for the treatment of PARPis-induced GI toxicities due to lack of controlled studies addressing the subject. The philosophy of management of anticancer-related GI toxicities extends to employing some nutritional interventions. In a recent Cochrane review evaluating how to minimize the frequency of diarrhea associated with pelvic radiotherapy, the authors found that combinations of modified fat, lactose-restriction, fat-restriction and fiber supplementation was recommended to reduce to the frequency of diarrhea.[@b35-dddt-12-3013] Additionally, according to the package insert of approved PARPis,[@b36-dddt-12-3013]--[@b38-dddt-12-3013] if grade three or higher non-hematological toxicity occurs, temporary dose interruption and/or dose reduction to half the dose previously administered should be considered based on tolerability and severity.

A number of limitations are needed to be acknowledged: first, as with any similar meta-analysis, the pooled results of our study are significantly affected by the confounding factors of individual studies that are chosen. Second, this meta-analysis only includes published trials, and a meta-analysis of individual level data might define more clearly treatment benefits in specific subgroups. Third, heterogeneity is observed in some of the RR analyses. This may be related to the different PARPis for the RR analysis, and differences in sample size, although we have tried to minimize its influence by using the random-effect model. Finally, as the present meta-analysis excludes Phase I trials, the impact of PARPis dose/schedules on the risk of gastrointestinal toxicities could not be fully assessed in this analysis.

Conclusion
==========

Our study suggests that the risk of all-grade gastrointestinal toxicities associated with PARPis is significantly increased in ovarian cancer patients receiving these drugs. And the use of PARPis significantly increased the risk of developing high-grade nausea and vomiting, but not for diarrhea and constipation. Although the rate of clinically high-grade GI toxicities is very low, clinicians should be aware of these risks and perform regular assessment for such toxicities during administration of these drugs. Additionally, further research into the pathogenesis of these toxicities is still needed.
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###### 

Baseline characteristics of included trials

  Author                                           Patient enrolled   Phase   Treatment regimes                 Median age, years   Median PFS, months   No for analysis
  ------------------------------------------------ ------------------ ------- --------------------------------- ------------------- -------------------- -----------------
  Audeh et al, 2010[@b27-dddt-12-3013]             57                 II      Olaparib 400 mg bid               54                  NR                   57
  Gelmon et al, 2011[@b26-dddt-12-3013]            65                 II      Olaparib 400 mg bid               58                  7.1                  65
  Kaye et al, 2012[@b25-dddt-12-3013]              97                 II      Olaparib 200 mg bid               58.5                6.5                  64
                                                                              Pegylated liposomal doxorubicin   53                  7.1                  33
  Ledermann et al, 2012[@b24-dddt-12-3013]         265                II      Olaparib 400 mg bid po            58                  8.4                  136
                                                                              Placebo                           59                  4.8                  128
  Liu et al, 2014[@b31-dddt-12-3013]               90                 II      Olaparib 400 mg bid po            57.8                9                    46
  Coleman et al, 2015[@b30-dddt-12-3013]           50                 II      Veliparib 400 mg bid po           57                  8.18                 50
  Bell-McGuinn et al, 2016[@b29-dddt-12-3013]      12                 II      Iniparib 8 mg/kg                  NR                  NR                   12
  Domchek et al, 2016[@b28-dddt-12-3013]           154                II      Olaparib 400 mg bid po            58                  NR                   154
  Mirza et al, 2016[@b21-dddt-12-3013]             553                III     Niraparib 300 mg qd po            57                  21                   367
                                                                              Placebo                           58                  5.5                  179
  Pujade-Lauraine et al, 2017[@b23-dddt-12-3013]   295                III     Olaparib 150 mg bid po            56                  19.1                 195
                                                                              Placebo                           56                  5.5                  99
  Swisher et al, 2017[@b32-dddt-12-3013]           206                II      Rucaparib 600 mg bid po           NR                  NR                   206
  Coleman et al, 2017[@b22-dddt-12-3013]           564                III     Rucaparib 600 mg bid po           61                  16.6                 375
                                                                              Placebo                           62                  5.4                  189

**Abbreviations:** NR, not reported; PFS, progression-free survival; Bid, bis in die; Po, per os.

###### 

Incidence of adverse outcomes for clinical trials included in the meta-analysis

  Adverse outcome   Grade           Trials   Events   No of patients   Incidence, % (95% CI)   I[@b2-dddt-12-3013]
  ----------------- --------------- -------- -------- ---------------- ----------------------- ---------------------
  Nausea            All-grade       12       1,225    1,727            68.8 (63.5--73.6)       76
                    Grade 3 and 4   12       53       1,727            3.4 (2.6--4.5)          0
  Vomiting          All-grade       10       611      1,669            36.2 (30.9--41.8)       76
                    Grade 3 and 4   10       39       1,669            2.0 (1.4--3.0)          0
  Diarrhea          All-grade       11       433      1,677            25.3 (21.2--29.8)       70
                    Grade 3 and 4   11       21       1,677            1.7 (1.0--3.0)          38
  Constipation      All-grade       9        476      1,566            25.3 (17.9--34.5)       92
                    Grade 3 and 4   9        16       1,566            1.4 (0.9--2.3)          0
